索利那新与托特罗定治疗前列腺增生伴膀胱过度活动症效果比较被引量：1

下载PDF

导出

摘要目的探讨索利那新与托特罗定治疗前列腺增生(BPH)伴膀胱过度活动症(OAB)的疗效。方法选择2015年6月至2 01 6年6月该院收治的9 4例B PH伴O AB患者为观察对象,按治疗方法不同分为观察组与对照组各47例。两组均进行排尿训练,逐渐延长排尿间隔,并给予多沙唑嗪,在此基础上对照组口服酒石酸托特罗定片,观察组采用琥珀酸索利那新片治疗。观察疗效及不良反应,比较两组治疗前后膀胱过度活动症评分(OABSS)、国际前列腺症状评分(IPSS)、最大尿流率(Qmax)及残余尿量。结果观察组治疗总有效率(87.2%)明显高于对照组(66.0%),OABSS评分、IPSS评分、Qmax、残余尿量均优于对照组;两组不良反应发生率接近。结论索利那新治疗BPH伴OAB效果良好,可联合α受体阻滞药,避免引起排尿障碍。

作者翁锡君金展鲲钱增兴吴齐全

机构地区宁波市泌尿肾病医院泌尿外科

出处《中国乡村医药》 2017年第12期11-12,共2页

关键词托特罗定索利那新前列腺增生膀胱过度活动症

分类号 R697.3 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献4

1高中伟,辛士永,张建国,任小强,尚亚锋,张惟,李会兵,肖飞,邵长帅.坦索罗辛联合索利那新在治疗轻中度良性前列腺增生合并膀胱过度活动症中的疗效分析[J].中华男科学杂志,2014,20(3):239-243. 被引量：28
2刘胜,余昆,李风,余志海,杨忠新,夏宗禹.索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻[J].重庆医科大学学报,2013,38(3):330-332. 被引量：13
3刘秉乾,李建华,王义昆,武玉东.M受体阻滞剂联合α受体阻滞剂治疗膀胱过度活动症合并膀胱出口梗阻的Meta分析[J].中华外科杂志,2014,52(5):376-380. 被引量：9
4刘秉乾,李沛寰,李建华,王义昆,武玉东.索利那新与托特罗定治疗膀胱过度活动症效果及安全性的荟萃分析[J].中华医学杂志,2014,94(30):2350-2354. 被引量：13

二级参考文献48

1肖河,李汉忠,杨勇,黄钟明,李永强,赵晓峰.M-受体与α-受体阻滞剂联合用药治疗良性前列腺增生及下尿路症状的临床观察[J].中华医学杂志,2007,87(23):1590-1593. 被引量：6
2Lee S H,Chung B H,Kim S J,et al.Initial combined treatment with anticholinergics and a-blockers for men with lower urinary tract symp- toms related to BPH and overactive bladder:a prospective,randomized, multi-center, double-blind, placebo-controlled study[J].Prostate Cancer Prostatic Dis, 2011,14(4) : 320-325.
3Park S C,Lee J W,Rim J S.The relationship between intravesical prostatic protrusion and pressure flow study findings in patients with benign prostate obstruction/lower urinary tract symptoms[J].Actas Urol Esp, 2012,36(3) : 165-170.
4Irw in De,Milsom I,hunskaar S,et al.Population-based survey of urinary, incontinence,overactive bladder and other lower urinary tract symptoms in five countries:results of the EPIC study[J].Eur Urol,2006, 50(6) : 1306-1315.
5Lee K S,Choo M S,Kim D Y,et al.Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastroin- testinal therapeutic system formulation for overactive bladder and coex- isting benign prostatic obstruction: a prospective, randomized, controlled multicenter study[J].J Urol, 2005,174(4 Pt 1 ) : 1334-1338.
6Ohtake A,Ukai M, Hatanaka T.In vitro and in vivo tissue selectivity profile of solifenacin sueeinate(YM905) for urinary bladder over salivary gland in rats[J].Eur J Pharmacol, 2004,492 ( 2-3 ) : 243.
7Herschom S,Stothers L,Carlson K,et al.Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial[J].J Urol, 2010,183 (5) : 1892-1898.
8Chung D E,Te A E,Staskin D R,et al.Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates>30 grams[J].Urology, 2010,75 (5) : 1144-1148.
9Knutson T, Edlund C, Fall M, et al. BPH with coexisting over- active bladder dysfunction -- an everyday urological dilemma. Neurourol Urodyn, 2001, 20(3): 237-247.
10Dmochowski R. Antimuscarinic therapy in men with low urinary tract symptoms: What is the evidence? Curr Urol Rep, 2006, 7 (6) : 462-467.